AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34357466
Drug: Pantoprazole 80
RxNorm normalized name: pantoprazole 80 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 80 mg with cisplatin
Trial: 34357466
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg with cisplatin
Trial: 32281641
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy during hospitalization
Trial: 32281641
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy after discharge
Trial: 35148036
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment protocol
Trial: 32466710
Drug: Alcoholic drink
RxNorm normalized name: Alcoholic drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic drink (0.4 g/kg)
Trial: 37318120
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with 8 mg intravenous ondansetron
Trial: 32333793
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.5 g daily for four months)
Trial: 33260552
Drug: Oolong tea
RxNorm normalized name: oolong tea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oolong tea (100 mg caffeine, 21.4 mg gallic acid, 97 mg catechins, 125 mg polymerized polyphenol)
Trial: 34693501
Drug: Metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.2 mg/kg three times daily, administered 15 min before feeding, up to term.
Trial: 36172027
Drug: Idebenone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idebenone (30 mg each time, three times a day)
Trial: 35379286
Drug: Intra-arterial vasodilatory
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial vasodilatory therapy (prostaglandin infusion)
Trial: 32430540
Drug: Alcohol (male:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (male: 0.55 g/kg, female: 0.45 g/kg)
Trial: 32285710
Drug: Water (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (250 mL)
Trial: 33565516
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONSs)
Trial: 36358943
Drug: Pregnenolone (PREG)
DrugBank: Pregnenolone acetate (DB14626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (PREG) 500 mg/day
Trial: 36358943
Drug: Pregnenolone (PREG)
DrugBank: Pregnenolone acetate (DB14626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (PREG) 300 mg/day
Trial: 33353913
Drug: 31 gauge
RxNorm normalized name: lancets 31 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 31 gauge needle with topical lignocaine‐prilocaine (31GT)
Trial: 33353913
Drug: 27 gauge
RxNorm normalized name: 1mL 27 gauge, 0.5 inch syringe with needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 gauge needle with topical lignocaine‐prilocaine (27GT)
Trial: 35796486
Drug: Ketamine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (75 mg) with 1 mg midazolam
Trial: 35796486
Drug: Standard Moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Moderate Sedation (SMS) with midazolam and fentanyl (150 mcg fentanyl, 5 mg midazolam)
Trial: 34859459
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous selenium supplementation (3000 mcg after anesthesia induction, 1000 mcg upon ICU admission, and 1000 mcg daily in the ICU for a maximum of 14 days)
Trial: 32471143
Drug: Serum ANP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum ANP levels >64.6 pg/mL
Trial: 32471143
Drug: Serum NT-proCNP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum NT-proCNP levels >1.7 pg/mL
Trial: 33785406
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with traumatic memory reactivation
Trial: 33785406
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with non-traumatic memory reactivation
Trial: 34398796
Drug: WeChat-supported platform,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WeChat-supported platform, Medication Housekeeper (MediHK) for 4 weeks, including daily pain diaries, ADR forms every 3 days, and Brief Pain Inventory every 15 days.
Trial: 34398796
Drug: WeChat-supported platform,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WeChat-supported platform, Medication Housekeeper (MediHK) for 4 weeks.
Trial: 35182889
Drug: internet-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive-behavioral therapy (ICBT) (iSOMA) for 8 weeks
Trial: 33599356
Drug: E6011 (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 (12-week multiple ascending dose phase: 2, 5, 10, and 15 mg/kg intravenously every 2 weeks)
Trial: 33599356
Drug: E6011 (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 (12-week multiple ascending dose phase)
Trial: 33599356
Drug: E6011 (40-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 (40-week Extension phase at the same dose as MAD phase)
Trial: 33248978
Drug: Drug-Eluting Stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stent (EES)
Trial: 33753275
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (open reduction and screw fixation)
Trial: 33753275
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (pressure bandage)
Trial: 32243100
Drug: Conventional diuretic
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diuretic therapy (n = 26)
Trial: 32773594
Drug: Tapentadol extended-release
RxNorm normalized name: Tapentadol Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol extended-release (ER) 50 mg × 2
Trial: 32773594
Drug: Oxycodone controlled-release
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone controlled-release (CR) 10 mg × 2
Trial: 33789722
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injection into the cricopharyngeal muscle
Trial: 33671310
Drug: Grape Seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape Seed Extract (GSEe) 300 mg/day for 16 weeks
Trial: 37000390
Drug: Semaglutide 1
RxNorm normalized name: semaglutide 14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1 mg
Trial: 32440938
Drug: 3% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% prilocaine with 0.03 IU/mL felypressin (Prilo/Fely)
Trial: 32745768
Drug: Coffee A
RxNorm normalized name: White Glo Coffee and Tea Stain Remover Fluoride Anticavity KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee A (787 mg CGAs/day)
Trial: 32745768
Drug: Coffee B
RxNorm normalized name: Coffee Bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee B (407 mg CGAs/day)
Trial: 36308079
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 20 mg·kg‐1
Trial: 33302802
Drug: 90 ml
RxNorm normalized name: 190 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 ml sea buckthorn puree for 90 days
Trial: 33626904
Drug: Warfarin (later
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (later use at 1 week post-TIA or 2 weeks post-AIS)
Trial: 33626904
Drug: Warfarin (later
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (later use)
Trial: 32376110
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) hepatitis A vaccine
Trial: 32376110
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) hepatitis A vaccine
Trial: 33621009
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin 5mg orally once daily
Trial: 33621009
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pregabalin and solifenacin
Trial: 32291094
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses thromboprophylaxis
Trial: 36267027
Drug: Dietary fiber
RxNorm normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fiber supplementation (19.56 g day‐1)
Trial: 33618051
Drug: Interval exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval exercise (IE) - 30 min at 100% peak work capacity (WRpeak) for 30s alternated with 40% WRpeak for 30s, 3 times weekly for 12 weeks
Trial: 33618051
Drug: Constant-load exercise
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant-load exercise (CLE) - 30 min at 70% WRpeak, 3 times weekly for 12 weeks
Trial: 34009282
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy (CBT) for 12 weeks (n = 51)
Trial: 32386068
Drug: Noncultured epidermal
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncultured epidermal cell suspension (NCES)
Trial: 34416295
Drug: Detoxifying and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detoxifying and blood-activating Chinese medicine granules (15 g of Polygonum cuspidatum and 10 g of Crataegus pinnatifida for 4 weeks)
Trial: 34416295
Drug: Standardized Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Western medicine (control group)
Trial: 32870471
Drug: Once-weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly semaglutide 0.5 mg
Trial: 36651820
Drug: Once-weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly semaglutide 1.0 mg
Trial: 33074557
Drug: Once-daily sitagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily sitagliptin 100 mg
Trial: 33074557
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of semaglutide
Trial: 33026160
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg (ExQW)
Trial: 35642157
Drug: Mirror Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Therapy (MT) - corresponding movements of limbs, 15 min, 5 d/week for 2 weeks
Trial: 32209798
Drug: Modified lower-calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified lower-calorie diet (MD) for 12 weeks, reducing daily energy intake by 30%
Trial: 32496449
Drug: Atropine 0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.004 mg/kg intravenously
Trial: 35086737
Drug: pharmacogenomic-driven chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmacogenomic-driven chemotherapy
Trial: 35086737
Drug: standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard adjuvant chemotherapy
Trial: 32536013
Drug: Abemaciclib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib (150 mg twice daily) plus nonsteroidal aromatase inhibitor (NSAI)
Trial: 32536013
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nonsteroidal aromatase inhibitor (NSAI)
Trial: 32272959
Drug: 12.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 μg misoprostol sublingually
Trial: 32272959
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg misoprostol vaginally
Trial: 35086385
Drug: Orbital atherectomy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital atherectomy (OA) with adjunctive drug-coated balloon (DCB) angioplasty
Trial: 34837899
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) intervention, 6 sessions every 2 days
Trial: 32920647
Drug: BUP‐XR (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP‐XR (extended-release subcutaneous buprenorphine)
Trial: 35853489
Drug: Monthly injection
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly injection of pegcetacoplan (AM)
Trial: 35853489
Drug: Injection every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection every other month of pegcetacoplan (AEOM)
Trial: 36367998
Drug: Enzalutamide (ENZA)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (ENZA) 160 mg once daily for 6 months
Trial: 34666767
Drug: JTA-200/2 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTA-200/2 (200 μg clonidine and 20 mg hyaluronic acid in 2 ml)
Trial: 34666767
Drug: JTA-004 (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTA-004 (pooled data from all formulations)
Trial: 34666767
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment (hylan G-F 20)
Trial: 35794728
Drug: Coloring therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coloring therapy combined with conventional therapy
Trial: 35794728
Drug: Conventional antianxiety
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antianxiety medication and physical therapy
Trial: 32362479
Drug: Flurbiprofen patch
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen patch (FPP)
Trial: 32362479
Drug: S-Flurbiprofen patch
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-Flurbiprofen patch (SFPP)
Trial: 32362479
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no patch)
Trial: 36323482
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care approach including app-intervention, two telephone counselling sessions (50 min each), and online therapy over 17 weeks (15 weekly group sessions, 8 individual sessions).
Trial: 37901346
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 and 300 mg every 2 weeks
Trial: 35988464
Drug: Intrapartum azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrapartum azithromycin (2g oral)
Trial: 34823296
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (281 patients)
Trial: 34823296
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy (285 patients)
Trial: 34713987
Drug: PB2452 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB2452 6 g i.v. bolus followed by 6 g infused over 4 h and then 6 g over 12 h
Trial: 33857436
Drug: ENDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENDS with 36 mg/mL nicotine
Trial: 33857436
Drug: ENDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENDS with 0 mg/mL nicotine
Trial: 33857436
Drug: ENDS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENDS with 8 mg/mL nicotine
Trial: 36268807
Drug: Neurotec® herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotec® herbal capsule (100 mg twice a day for three months)
Trial: 34837931
Drug: Mucosamin spray
RxNorm normalized name: chondroitin sulfates / glucosamine Oral Tablet [Cosamin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosamin spray (3-4 times a day)
Trial: 34837931
Drug: Standard medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medications (3 times a day)
Trial: 35134800
Drug: Tablet of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of innovator product (FSt)
Trial: 33546734
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of RAAS inhibitors
Trial: 33546734
Drug: Temporary discontinuation
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary discontinuation of RAAS inhibitors
Trial: 34580114
Drug: Veliparib plus
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib plus modified FOLFIRI (veliparib 200 mg twice daily, days 1-7 with mFOLFIRI days 3-5)
Trial: 37669281
Drug: Supported Protocolized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported Protocolized Discontinuation (SPD) alone
Trial: 35450055
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (3 mg/kg/day for 5 days)
Trial: 35450055
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline infusion (50 ml/day for 5 days)
Trial: 32536425
Drug: TPVB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPVB with 20 mL 0.25% bupivacaine
Trial: 36342252
Drug: 532-nm picosecond
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532-nm picosecond laser treatment (3 monthly treatments, 800 ps pulse duration, 4-6mm spot size, 0.1 to 0.6J/cm2 fluence)
Trial: 36342252
Drug: 532-nm picosecond
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532-nm picosecond laser treatment
Trial: 33756525
Drug: High-quality multi-ingredient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality multi-ingredient nutritional supplement (SUPP) - 20 g whey protein, 2 g leucine, 2.5 g creatine monohydrate, 300 mg calcium citrate, 1000 IU vitamin D, ingested twice daily
Trial: 33756525
Drug: Isontrogenous isoenergetic
RxNorm normalized name: Octisalate 0.05 g in 1 mL / Avobenzone 0.03 g in 1 mL / Octinoxate 0.029 g in 1 mL / Octocrylene 0.022 g in 1 mL TOPICAL LOTION [For Men Maca Root Energetic Face Protector SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isontrogenous isoenergetic placebo (PL) - 20 g collagen peptides, 1.4 g alanine, 0.6 g glycine, ingested twice daily
Trial: 33756525
Drug: High-quality multi-ingredient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality multi-ingredient nutritional supplement (SUPP)
Trial: 34611051
Drug: Astaxanthin 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin 6 mg/day for 4 weeks
Trial: 33819166
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy with bilevel positive airway pressure (BiPAP) ventilation
Trial: 33819166
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative respiratory and physical therapy techniques
Trial: 32021143
Drug: Glycopyrrolate/formoterol fumarate
RxNorm normalized name: glycopyrrolate/formoterol fumarate 9/4.8 MCG/INHAL Metered Dose Inhaler, 120 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Trial: 32949031
Drug: Ceftolozane/tazobactam (C/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam (C/T) 3-g dose (2 g ceftolozane and 1 g tazobactam) administered via a 1-hour infusion every 8 hours
Trial: 33653009
Drug: High-NO3- (HN:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-NO3- (HN: 2 × 70 mL BJ/day)
Trial: 33653009
Drug: Medium-NO3- (MN:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-NO3- (MN: 70 mL BJ/day)
Trial: 33653009
Drug: Low-NO3- (LN:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-NO3- (LN: 70 mL BJ on alternate days)
Trial: 33653009
Drug: Placebo (PL:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL: 70 mL of NO3--depleted BJ on alternate days)
Trial: 35907163
Drug: Indoor daylight
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor daylight photodynamic therapy (idl‐PDT)
Trial: 32229771
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training with protein supplement (21 g whey protein per day, 90 kcal)
Trial: 38140854
Drug: Intravenous belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous belimumab 10 mg/kg